Hot Life Science Investor Mandate 2: Cross-Border VC Firm Investing in Therapeutics

19 Nov

A cross-border venture capital firm has offices in Northeastern US and Japan. The firm invests in early-stage therapeutic companies worldwide, with a focus on opportunities in North America. The firm may allocate up to $15 million per opportunity, but the amount initially committed varies dependent on the company’s stage of development, from under $1 million to $3-5 million for companies raising funds for IND-enabling studies.

The firm only invest in therapeutics, and are primarily focused on companies with preclinical assets. Within therapeutics, both small molecule and biologic opportunities are of interest. The firm may invest up to 18 months prior to IND, but require that a company has a lead asset that has been characterized, and has obtained proof of concept animal data that shows how the drug’s mechanism of action is playing out in the animal model. The firm also prefers that a company has additional follow-on drug candidates. In addition to preclinical opportunities, the firm also very selectively invests in companies with clinical-stage programs, but only in cases where the firm can add significant strategic value. The firm will consider opportunities in any indication area.

The firm invests in teams with experienced, highly motivated teams with a strong background in either life science research or industry. The firm only invests in companies with technology that has the potential to be first in class.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: